City Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of CITY-RBP4 for the Treatment of Stargardt Disease Nov 10 Written by Guest User https://investors.citytx.com/news-releases/news-release-details/city-therapeutics-announces-first-participant-dosed-phase-1 Press Release Guest User Next Next Phase 1 Data for CITY-FXI, an RNAi Therapeutic Candidate for Thromboembolic Diseases, Selected for Oral Presentation at the 68th ASH Annual Meeting
City Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of CITY-RBP4 for the Treatment of Stargardt Disease Nov 10 Written by Guest User https://investors.citytx.com/news-releases/news-release-details/city-therapeutics-announces-first-participant-dosed-phase-1 Press Release Guest User
